Weight gain is common in patients with severe mental illness and contributes to cardiovascular risk. Medications, such as antipsychotics, antidepressants, and mood stabilizers, are commonly associated with weight gain. In addition, antidiabetic drugs (insulin, sulfonylureas, and thiazolidinediones), antihypertensives (beta-blockers), and corticosteroids, which are commonly used to treat comorbid medical conditions, contribute to weight gain. In clinical practice, simple measures, such as body weight, body mass index, and waist circumference, can be used to monitor the metabolic risk of psychotropic drugs. Lifestyle modifications, including dietary advice and exercise, help in preventing weight gain. The clinician can choose relatively weight-neutral drugs for the treatment of psychiatric disorders. For the patients having weight gain with psychotropic drugs, several nonpharmacological and pharmacological management strategies are available.
Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374(9690):620–627. DOI: 10.1016/S0140-6736(09)60742-X.
Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014;10:425–448. DOI: 10.1146/annurev-clinpsy-032813-153657.
Jayatilleke N, Hayes RD, Dutta R, et al. Contributions of specific causes of death to lost life expectancy in severe mental illness. Eur Psychiatry 2017;43:109–115. DOI: 10.1016/j.eurpsy.2017.02.487.
Rajan TM, Menon V. Psychiatric disorders and obesity: a review of association studies. J Postgrad Med 2017;63(3):182–190. DOI: 10.4103/jpgm.JPGM_712_16.
Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophrenia Bulletin 2013;39(2):306–318. DOI: 10.1093/schbul/sbr148.
Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013;170(3): 265–274. DOI: 10.1176/appi.ajp.2012.12050620.
Chadda RK, Ramshankar P, Deb KS, et al. Metabolic syndrome in schizophrenia: differences between antipsychotic-naïve and treated patients. J Pharmacol Pharmacother 2013;4(3):176–186. DOI: 10.4103/0976-500X.114596.
Ho-Pham LT, Lai TQ, Nguyen MTT, et al. Relationship between body mass index and percent body fat in Vietnamese: implications for the diagnosis of obesity. PLoS One 2015;10(5):e0127198. DOI: 10.1371/journal.pone.0127198.
Misra P, Singh AK, Archana S, et al. Relationship between body mass index and percentage of body fat, estimated by bio-electrical impedance among adult females in a rural community of North India: a cross-sectional study. J Postgrad Med 2019;65(3):134–140. DOI: 10.4103/jpgm.JPGM_218_18.
Misra A. Ethnic-specific criteria for classification of body mass index: a perspective for Asian Indians and American Diabetes Association position statement. Diabetes Technol Ther 2015;17(9):667–671. DOI: 10.1089/dia.2015.0007.
World Health Organization. Obesity, prevention and managing the global epidemic. Report of a WHO consultation on obesity. Geneva: World Health Organization; 1998.
Kuriyan R. Body composition techniques. Indian J Med Res 2018;148(5):648–658. DOI: 10.4103/ijmr.IJMR_1777_18.
Fang H, Berg E, Cheng X, et al. How to best assess abdominal obesity. Curr Opin Clin Nutr Metab Care 2018;21(5):360–365. DOI: 10.1097/MCO.0000000000000485.
Dent R, Blackmore A, Peterson J, et al. Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS One 2012;7(6):e36889. DOI: 10.1371/journal.pone.0036889.
Shrivastava A, Johnston ME. Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management. Mens Sana Monogr 2010;8(1):53–68. DOI: 10.4103/0973-1229.58819.
Gracious BL, Meyer AE. Psychotropic-induced weight gain and potential pharmacologic treatment strategies. Psychiatry (Edgmont) 2005;2(1):36–42.
Musil R, Obermeier M, Russ P, et al. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf 2015;14(1):73–96. DOI: 10.1517/14740338.2015.974549.
Bak M, Fransen A, Janssen J, et al. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014;9(4):e94112. DOI: 10.1371/journal.pone.0094112.
Venkatasubramanian G, Rao NP, Arasappa R, et al. A longitudinal study of relation between side-effects and clinical improvement in schizophrenia: is there a neuro-metabolic threshold for second generation antipsychotics? Clin Psychopharmacol Neurosci 2013;11(1):24–27. DOI: 10.9758/cpn.2013.11.1.24.
Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ 2018;361:k1951. DOI: 10.1136/bmj.k1951.
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71(10):1259–1272. DOI: 10.4088/JCP.09r05346blu.
Baptista T, Kin NMKNY, Beaulieu S, et al. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002;35(6):205–219. DOI: 10.1055/s-2002-36391.
Schwartz TL, Nihalani N, Jindal S, et al. Psychiatric medication-induced obesity: a review. Obes Rev 2004;5(2):115–121. DOI: 10.1111/j.1467-789X.2004.00139.x.
McFarlane SI. Antidiabetic medications and weight gain: implications for the practicing physician. Curr Diab Rep 2009;9(3):249–254. DOI: 10.1007/s11892-009-0040-7.
Wharton S, Raiber L, Serodio KJ, et al. Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes Metab Syndr Obes 2018;11:427–438. DOI: 10.2147/DMSO.S171365.
Holt RIG. The management of obesity in people with severe mental illness: an unresolved conundrum. Psychother Psychosom 2019;88(6):327–332. DOI: 10.1159/000503835.
De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10(2):138–151. DOI: 10.1002/j.2051-5545.2011.tb00036.x.
Bushe C, Haddad P, Peveler R, et al. The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol 2005;19:28–35. DOI: 10.1177/0269881105058682.
Bort-Roig J, Briones-Buixassa L, Felez-Nobrega M, et al. Sedentary behaviour associations with health outcomes in people with severe mental illness: a systematic review. Eur J Public Health 2020;30(1): 150–157. DOI: 10.1093/eurpub/ckz016.
Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168(9):947–956. DOI: 10.1176/appi.ajp.2011.10111609.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65(2):267–272. DOI: 10.4088/jcp.v65n0219.
McCreadie RG, Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534–539. DOI: 10.1192/bjp.183.6.534.
Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29(3):697–701. DOI: 10.1017/s0033291798008186.
Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110(18):2952–2967. DOI: 10.1161/01.CIR.0000145546.97738.1E.
Lean M, Fornells-Ambrojo M, Milton A, et al. Self-management interventions for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 2019;214(5):260–268. DOI: 10.1192/bjp.2019.54.
Miller W, Rolinick S. Motivational interviewing: helping people change. New York: Guilford Press; 2013.
Vandenberghe F, Gholam-Rezaee M, Saigí-Morgui N, et al. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry 2015;76(11):e1417–e1423. DOI: 10.4088/JCP.14m09358.
Hiluy JC, Nazar BP, Gonçalves WS, et al. Effectiveness of pharmacologic interventions in the management of weight gain in patients with severe mental illness: a systematic review and meta-analysis. Prim Care Companion CNS Disord 2019;21(6):19r02483. DOI: 10.4088/PCC.19r02483.
Wu R-R, Zhao J-P, Guo X-F, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008;165(3):352–358. DOI: 10.1176/appi.ajp.2007.07010079.
Praharaj SK. Metformin for lithium-induced weight gain: a case report. Clin Psychopharmacol Neurosci 2016;14(1):101–103. DOI: 10.9758/cpn.2016.14.1.101.
Praharaj SK, Jana AK, Goyal N, et al. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol 2011;71(3):377–382. DOI: 10.1111/j.1365-2125.2010.03783.x.
Zhuo C, Xu Y, Liu S, et al. Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis. Front Pharmacol 2018;9:1393. DOI: 10.3389/fphar.2018.01393.
Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014;40(6):1385–1403. DOI: 10.1093/schbul/sbu030.
Fleischhacker WW, Heikkinen ME, Olié J-P, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010;13(8):1115–1125. DOI: 10.1017/S1461145710000490.
Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 2017;74:719–728. DOI: 10.1001/jamapsychiatry.2017.1220.
Jeyaraj S, Shetty AS, Kumar CRR, et al. Liraglutide-induced acute pancreatitis. J Assoc Physicians India 2014;62(1):64–66.
Perrio MJ, Wilton LV, Shakir SAW. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity 2007;15(11):2712–2722. DOI: 10.1038/oby.2007.323.
Li M-F, Cheung BM. Rise and fall of anti-obesity drugs. World J Diabetes 2011;2(2):19–23. DOI: 10.4239/wjd.v2.i2.19.
Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry 2020;177(12):1168–1178. DOI: 10.1176/appi.ajp.2020.19121279.
Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:706–711. DOI: 10.4088/jcp.v69n0503.
Elmslie JL, Porter RJ, Joyce PR, et al. Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar Disord 2006;8:503–507. DOI: 10.1111/j.1399-5618.2006.00345.x.
Bustillo JR, Lauriello J, Parker K, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 2003;28:527–529. DOI: 10.1038/sj.npp.1300089.
Dayabandara M, Hanwella R, Ratnatunga S, et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 2017;13:2231–2241. DOI: 10.2147/NDT.S113099.
Tek C, Ratliff J, Reutenauer E, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept. J Clin Psychopharmacol 2014;34(5):608–612. DOI: 10.1097/JCP.0000000000000192.
Lasserre AM, Glaus J, Vandeleur CL, et al. Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass: a prospective, population-based study. JAMA Psychiatry 2014;71(8):880–888. DOI: 10.1001/jamapsychiatry.2014.411.
Kaskie RE, Graziano B, Ferrarelli F. Schizophrenia and sleep disorders: links, risks, and management challenges. Nat Sci Sleep 2017;9: 227–239. DOI: 10.2147/NSS.S121076.